Aug 18 (Reuters) – Alphamab Oncology: * NMPA ACCEPTS NDA FOR ANBENITAMAB (KN026) WITH HB1801 FOR HER2+ ADVANCED BREAST CANCER Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
New Serena Williams Barbie pays homage to tennis player's 2005 Australian Open victory
VIDEO SHOWS: U.S. TENNIS PLAYER SERENA WILLIAMS WITH BARBIE DOLL IN HER LIKENESS / STILL…
African Markets – Factors to watch on Oct 9
NAIROBI, Oct 9 (Reuters) - The following company announcements, scheduled economic indicators, debt and currency…
Nvidia-backed Firmus scraps $5 billion Australian IPO on poor demand
By Scott Murdoch and Christine Chen SYDNEY, Oct 9 (Reuters) - Australia's Firmus, a data…
